As I pointed out previously, management are planning to pursue...

As I pointed out previously, management are planning to pursue FDA approval. First though, they will get Colostat on the market via a CLIA lab because it's quicker.

Please note that alongside Australia, Rhythm have a strong focus on marketing in many countries in Asia and Europe, particularly those where governments utilise the FIT test for mass screening their populations. The US is unique in this regard due to the highly privatised health system there whereby insurance companies relieve government of much of the screening test burden.